Indivior stock trades steadily as investors weigh recent earnings

Indivior stock (ISIN GB00BYZ0C031) is currently quoted at 34.94 dollars as of September 5, 2026, giving the specialty pharmaceuticals group a market capitalization of about 4.36 billion dollars according to market data from a US trading platform.

Earnings and valuation in focus

According to recent market data on Indivior Pharmaceuticals, the stock trades at a price-to-earnings ratio of 12.41 based on the latest available earnings figures, positioning it at a moderate valuation compared with many US-listed specialty drug makers.

On September 5, 2026, Indivior shares moved within an intraday range between 34.55 dollars and 35.31 dollars, with the closing level of 34.94 dollars sitting about 1.1% above the day’s low and 1.0% below the high, indicating relatively contained volatility on that trading day.

Recent trading range and investor perspective

For investors, the current price in the mid 30 dollar range is a reference point against the company’s recent earnings performance and longer term growth story in addiction treatment and behavioral health pharmaceuticals.

The same market data source reports a total market capitalization of approximately 4.36 billion dollars for Indivior as of September 5, 2026, a size that places the company among mid cap pharmaceutical names on US exchanges and makes it a potential candidate for investors seeking exposure to specialty therapies.

Key product segment

Indivior generates much of its revenue from medications used in the treatment of opioid use disorder and related conditions, a niche that remains central to its business model and investor narrative in the specialty pharmaceuticals space.

Stock price snapshot

Indivior stock closed at 34.94 dollars on its US trading venue on September 5, 2026, reflecting a mid cap valuation of around 4.36 billion dollars and serving as a current benchmark for investors following the company’s progress.